

# Funding Fundamentals


## Basics of Medicare Advantage Revenue

JANUARY 18, 2023

**Matt Kridgen, ASA, MAAA**  
Associate Actuary

**Ali Heinrich, FSA, MAAA**  
Consulting Actuary

**Jason Choi, FSA, MAAA**  
Consulting Actuary



# Agenda

- Part C revenue
- Low-income member considerations
- Part D revenue
- Part D settlement
- Risk adjustment basics


# Presenters



**Matt Kridgen**  
ASA, MAAA  
Associate Actuary  
[matt.kridgen@milliman.com](mailto:matt.kridgen@milliman.com)



**Ali Heinrich**  
FSA, MAAA  
Consulting Actuary  
[ali.heinrich@milliman.com](mailto:ali.heinrich@milliman.com)



**Jason Choi**  
FSA, MAAA  
Consulting Actuary  
[jason.choi@milliman.com](mailto:jason.choi@milliman.com)

# Funding fundamentals:

## Part C

# Sources of funding for Part C

## Medical and supplemental benefits

### CMS benchmarks

- Main source of revenue
- Funds Medicare-covered medicals costs at standard Medicare cost sharing
- Funds reduced cost sharing below standard Medicare\*
- Funds supplemental benefits \*
- Can also be used to fund members Part D premium \*
- Benchmarks are set at the county level
- Risk adjusted
- Quality component
- Rate announcement is released early in April each year

\* Funding reduced by savings percentage tied to Stars

### Member premiums or cost sharing

- Plans can charge members a monthly premium
  - Many plans with \$0 member premium
  - Buy down Part D premium as well
  - Must charge all members same premium
- Cost sharing reduces plan liability for medical benefits
  - Typically collected by providers

### Medicaid funding

- Members must be dual eligible for Medicare and Medicaid
- Medicaid pays or waives all cost sharing
  - Typically collected by providers
  - Most states have a “lesser of” policy
- Funds services not covered by Medicare
- Funds additional supplemental benefits
- Both D-SNP and general enrollment plans

# CMS benchmarks

## Part C benchmark calculation

### Benchmark =

$(\text{FFS Costs excluding IME}) * (\text{Quartile \%} + \text{Bonus \%})$

Quartile	Percentage of FFS costs
Highest cost quartile	95% of FFS costs
Second-highest cost quartile	100% of FFS costs
Third-highest cost quartile	107.5% of FFS costs
Lowest cost quartile	115% of FFS costs



# County benchmarks

## Ranking

Re-ranked annually

- Counties that change quartiles are transitioned for one year
  - Straight average of previous year multiplier and current year multiplier

## Bonus percentage

Plans with 4.0 stars and above will receive 5% bonus (subject to caps)

- 10% for double bonus counties
  - Urban counties with high Medicare Advantage enrollment and high star ratings
- 3.5% for new and low enrollment contracts

## Revenue and payment

- As of 2015, revenue (including quality bonus) cannot exceed benchmark under pre-ACA methodology
- Any potential reversals of the ACA or changes to the program may impact MA payment rates

# Part C Bid – Revenue calculation

Benchmark for 3.5 Star Plan	\$1,000	A
Projected plan risk score	1.100	B
Risk adjusted benchmark	\$1,100	$C = A * B$
Bid: Projected plan costs for traditional Medicare @ 1.1 risk score	\$950	D
Savings	\$150	$E = C - D$
Rebate percentage for 3.5 Star Plan	65%	F
Rebates	\$98	$G = E * F$
Plan revenue	\$1,048	$H = G + D$



# Savings and rebates




## Share $y\%$ of savings with plan, CMS retains $1-y\%$

- Savings % depends on quality star rating
  - 4.5 or 5.0 = 70%
  - New, low enrollment, 3.5, or 4.0 = 65%
  - 3.0 or lower = 50%
- Plan must spend savings




## Savings or rebate can be used to:

- Reduce cost sharing
- Pay for supplemental benefits
- Lower Part D member premium
- Lower member Part B premium
- All rebates must be used



# Medicare & Medicaid



# Low Income Premium Subsidy Amount (LIPSA)

## CMS subsidizes the monthly member premium

- LI members pay the difference between actual premium and LIPSA
- Important for D-SNPs and other plans targeting low-income membership to target LIPSA for premium
  - From a member’s perspective the plan has \$0 premium

**Subsidizes basic member premium only**

## Calculation of LIPSA

### Member income

### Premium subsidy percentage

<=135% FPL

100%

>135% and <= 140% FPL

75%

>140% FPL and <= 145% FPL

50%

>145 FPL and <150% FPL

25%

>=150% FPL (NLI)

0%

# Low Income Benchmarks (LIBs)

- **Low Income Premium Subsidy Amount (LIPSA)** reflects what CMS subsidizes for low-income members
  - LIBs may refer to bid amounts or premium amounts
  - LIB Bid amount = LIPSA + Direct Subsidy at 1.0
- LIBs reflect the **weighted average basic bid or premium** in each region
  - Like national average, unknown at initial bid submission
  - Plans must estimate this amount as part of initial submission
  - Usually published in late July / early August
  - Weighted based on LI members, including SNPs and PDPs
- 34 PD regions cover 50 states + 5 PD regions for US territories

2023 Low Income Premium Subsidy amounts		
Region	State(s)	Subsidy
1	NH, ME	31.10
2	CT, MA, RI, VT	36.27
3	NY	38.90
4	NJ	35.02
5	DE, DC, MD	39.22
6	PA, WV	41.08
7	VA	34.55
8	NC	38.38
9	SC	37.84
10	GA	37.30
11	FL	35.92
12	AL, TN	35.16
13	MI	32.65
14	OH	34.71
15	IN, KY	28.11
16	WI	43.10
17	IL	27.35

# Funding fundamentals:

## Part D

# Part D benefit design – 2022 and 2023

Total required revenue = net liability (for basic benefit) + administrative cost + required margin



Note: Non-LI members only. LI members receive LI cost sharing subsidy (LICS) from CMS for remainder of expected cost sharing above nominal copays.

# Part D revenue basics

## Bid calculations

**Total required revenue = net liability (for basic benefit) + administrative cost + required margin**

- Also known as the bid amount

**Total required revenue = direct subsidy + basic member premium**

- **Basic member premium** = bid at 1.0 – direct subsidy at 1.0
  - Subsidized for LI members
- **Direct subsidy:** Paid by CMS to MAO, adjusted for risk score

**Total member premium = basic premium + supplemental premium**

- **Supplemental premium** is only for enhanced plans

# Part D revenue basics

## Actual revenue received

### Risk-adjusted direct subsidy

- = Basic bid at risk score – basic member premium
- = (Risk score \* basic bid at 1.0) – basic member premium
- Amount is plan-specific and varies based on actual risk score


### Member premium

- Basic member premium = basic bid at 1.0 – direct subsidy at 1.0
- Supplemental member premium if Enhanced Alternative plan
  - *No subsidy or risk corridors available for supplemental benefits*
- Can be partially or fully bought down by Part C rebates on MAPD plans
- Same for all plan members regardless of Part D risk score



# Part D revenue basics

## Revenue dynamics



Source: [https://www.tpadministrator.com/internet/tpaw3\\_files.nsf/F/TPASponsor\\_CGDP\\_Onboarding\\_Training\\_112022\\_v3.pdf/\\$FILE/Sponsor\\_CGDP\\_Onboarding\\_Training\\_112022\\_v3.pdf](https://www.tpadministrator.com/internet/tpaw3_files.nsf/F/TPASponsor_CGDP_Onboarding_Training_112022_v3.pdf/$FILE/Sponsor_CGDP_Onboarding_Training_112022_v3.pdf)

# Funding fundamentals:

## Part D settlements

# Part D settlement components

## Reinsurance

- Subsidy estimated in the bid
  - Reinsurance in catastrophic phase less reinsurance DIR
- Subsidy paid to MAO each month
- Actual reinsurance calculated at year end
- Difference settled with CMS

## LICS

## Risk sharing

## CGDP

# Part D settlement components

## Reinsurance – Settlement calculation

### **Reinsurance settlement = actual reinsurance – reinsurance subsidy revenue**

- Actual reinsurance = allowable reinsurance costs x 0.80
- Allowable reinsurance costs = GDCA – reinsurance DIR
- Reinsurance DIR = DIR for covered drugs\* x [GDCA / (GDCB + GDCA)]

### **Negative settlement = amount MAO owes back to CMS**

### **Positive settlement = amount CMS owes to MAO**

GDCB = Gross drug cost below out-of-pocket threshold

GDCA = Gross drug cost above out-of-pocket threshold

\*DIR on Part D covered drugs. Excludes DIR on non-Part D drugs.

# Part D settlement components

## Reinsurance

- Subsidy estimated in the bid
  - Reinsurance in catastrophic phase less reinsurance DIR
- Subsidy paid to MAO each month
- Actual reinsurance calculated at year end
- Difference settled with CMS

## LICS

- Low-income cost sharing subsidy
- Subsidy estimated in the bid
- Subsidy paid to MAO each month
- Actual LICS calculated at year end
- Difference settled with CMS

## Risk sharing

## CGDP

## Part D settlement components

### Low-income Cost Sharing Subsidy (LICS) – Settlement calculation

#### **LICS settlement = LICS amounts from PDE – LICS revenue**

- Inflation Reduction Act: Beginning January 1, 2024, partial subsidy eliminated, transitioned to full subsidy
  - Beneficiaries between 135% and 150% FPL now eligible for full subsidy (larger LICS)

#### **Negative settlement = amount MAO owes back to CMS**

#### **Positive settlement = amount CMS owes to MAO**

# Part D settlement components

## Reinsurance

- Subsidy estimated in the bid
  - Reinsurance in catastrophic phase less reinsurance DIR
- Subsidy paid to MAO each month
- Actual reinsurance calculated at year end
- Difference settled with CMS

## LICS

- Low-income cost sharing subsidy
- Subsidy estimated in the bid
- Subsidy paid to MAO each month
- Actual LICS calculated at year end
- Difference settled with CMS

## Risk sharing

- Also known as “risk corridor”
- When actual costs differ materially from bid projections
- Actual costs calculated at year end
- Amount settled with CMS


## CGDP

# Risk sharing

## Settlement calculation

### Risk sharing settlement based on allowable costs compared to target amount

- Within 5%: No payment
- Over 5% and under 10%: Sharing 50% / 50%
- Over 10%: Sharing 80% CMS / 20% MAO
  - Includes 50% sharing over 5% and under 10%



Source: <https://www.medpac.gov/explainer-risk-sharing-mechanisms-in-part-d/#:~:text=Part%20D%20uses%20symmetric%20RISK,what%20the%20plan%20sponsor%20bid.>

# Part D settlement components

## Risk sharing – Settlement calculation

### Risk sharing settlement based on allowable costs compared to target amount

Target amount = (total direct subsidy payments + total basic premium) x (1 - administrative cost ratio from bid)

- Basic premium includes Part C rebate buy downs, low-income premium subsidies
- Administrative cost ratio = (total non-pharmacy expense + gain / loss) / total basic bid

Adjusted allowable risk corridor costs (AARCC) = (total CPP – reinsurance payments – DIR\*) / induced utilization ratio from bid

CPP = Covered Part D plan paid amount, or net amount the plan paid for standard Part D benefits (if the plan is a standard Part D plan or an enhanced plan) or for basic alternative or actuarial equivalent benefits

\*DIR on Part D covered drugs. Excludes DIR on non-Part D drugs.

# Part D settlement components

## Reinsurance

- Subsidy estimated in the bid
  - Reinsurance in catastrophic phase less reinsurance DIR
- Subsidy paid to MAO each month
- Actual reinsurance calculated at year end
- Difference settled with CMS

## LICS

- Low-income cost sharing subsidy
- Subsidy estimated in the bid
- Subsidy paid to MAO each month
- Actual LICS calculated at year end
- Difference settled with CMS

## Risk sharing

- Also known as “risk corridor”
- When actual costs differ materially from bid projections
- Actual costs calculated at year end
- Amount settled with CMS

## CGDP

- Coverage gap discount program
- Payments estimated in the bid
- Prospectively paid to MAO each month
- Actual CGDP calculated at year end
- Difference settled with CMS

## Part D settlement components

Coverage Gap Discount Program (CGDP) – Settlement calculation

**CGDP settlement = CGDP amounts from PDE – CGDP revenue from MMR**

- Inflation Reduction Act: Beginning January 1, 2025, CGDP eliminated
  - Replaced by Manufacturer Discount Program (MDP)

**Negative settlement = amount MAO owes back to CMS**

**Positive settlement = amount CMS owes to MAO**

# Inflation Reduction Act Subsidy Amount (IRASA)

Expected settlement

## For 2023 only

- Temporary retrospective subsidy
- For reduced cost sharing and deductibles for vaccines and insulins when not included in 2023 bids

- Memo released by CMS on September 26, 2022
- IRASA defined as the “difference between the beneficiary cost sharing for the covered insulin, or ACIP-recommended vaccine, under the plan’s 2023 benefit design, and the applicable statutory maximum cost sharing (\$35 for insulins and \$0 for vaccines).”
- Examples of IRASA calculations included in memo

Source: <https://www.cms.gov/files/document/irasapdeguidance508g.pdf>  
ACIP = Advisory Committee on Immunization Practices

# Funding fundamentals:

## Risk adjustment

# Risk score basics

## CMS-HCC models

- New enrollee
  - Applies to members with less than 12 months of Part B enrollment during the diagnosis collection period
  - Factor based only on age / gender / Medicaid / originally disabled status
- Community
  - Applies to majority of Medicare Advantage members
  - Also includes Hierarchical Condition Categories (HCCs)
- Institutional (Same as Community model, but different coefficients)
  - Also includes Hierarchical Condition Categories (HCCs)
- ESRD / Graft
  - Similar to Community, but with different set of HCCs and coefficients

## Calculation components

- CMS-HCC models
  - Demographics (age/gender/originally disabled)
  - HCCs including interactions
- FFS normalization
  - CMS adjustment to normalize total risk scores to 1.00
  - Varies by year and model
- MA coding pattern adjustment
  - Part C only
  - CMS adjustment to account for coding improvement over time
  - Varies by year (maybe)

# Risk score basics

## Medicare Advantage Risk Scores Are NOT ACA Risk Scores

### Differences

- Prospective (diagnoses from the prior year are used to calculate risk scores in the current year)
- Condition categories more appropriate for Medicare population
- Risk scores directly affect payments to insurers (no transfer calculation)
- Payment is from government to insurers and not between insurers



# Sample calculation

Raw

## D.B.

### Stats

- Female, 67 years old
- Aged in
- Not eligible for Medicaid

### Diagnoses

- HCC001 (1/7/2022)
- HCC085 (5/9/2022)
- HCC001 (5/9/2022)
- HCC018 (5/9/2022)
- HCC019 (8/12/2022)
- HCC017 (12/4/2022)

### Raw risk score

## Calculation

### Demographic coefficients

- 0.323

### HCC coefficients

- 0.335
- 0.331
- n/a
- ~~0.302~~
- n/a
- 0.302
- 1.291



# Sample calculation

Final

## D.B.

### Stats

- Female, 67 years old, Aged in, Not eligible for Medicaid

### Diagnoses

- HCC001 (1/7/2022)
- HCC085 (5/9/2022)
- HCC001 (5/9/2022)
- HCC018 (5/9/2022)
- HCC019 (8/12/2022)
- HCC017 (12/4/2022)

### Raw risk score

### Other factors

- Normalization
- Coding Pattern Adjustment

### Final risk score

## Calculation

### Demographic coefficients

- 0.323

### HCC coefficients

- 0.335
- 0.331
- n/a
- ~~0.302~~
- n/a
- 0.302

$$= 0.323 + 0.335 + 0.331 + 0.302 = 1.291$$

### Other factors

- 1.127
- 5.90%

$$= 1.291 / 1.127 * (1 - 5.90\%) = 1.078$$



## Bid risk score projection components

- Plan specific coding trend
  - Revenue only
- Population change
  - Should include a corresponding claims adjustment
- Expected CMS-HCC model changes

# Sample calculation – The bid picture

Real world calculation

Bid calculation*			Actual calculation*		
1.0 Benchmark (from bid)	\$1,000.00	A	Actual risk score	1.050	A
Risk Score (from bid)	1.020	B	1.0 bid	\$600.00	B
Risk Adj Benchmark	\$1,020.00	$C = A \times B$	County ISAR (from bid)	1.02	C
			Risk revenue	\$642.60	$D = A \times B \times C$
Bid	\$612.00	D			
1.0 Bid	\$600.00	$E = D / B$			
Savings	\$408.00	$F = C - D$			
Rebate	\$265.20	$G = F \times \text{Rebate \%}$			

\* excludes MSP and sequestration

# Sample calculation

What do I get paid?

## Plan level payments

- January risk score as of January payment: 1.00
- January risk revenue PMPM as of January payment: \$600.00
- Calculated risk score after “mid-year” update based on actual diagnoses: 1.03
- Accrual for January due to “mid-year” update: \$18.00 PMPM  
(0.03 \* \$600 PMPM)
- Historical increase in risk scores due to “final” update: 2%
- Estimated final risk score:  $1.03 * 1.02 = 1.0506$
- Accrual for January due to “final” update: \$12.36 PMPM  
(0.0206 \* \$600 PMPM)
- Total accrual if including “mid-year” and “final”: \$30.36 PMPM



## Other Part C revenue sources

- **Rebates allocated to MA**
- **Member premiums**
  - NOT risk adjusted



# What's the big deal anyway?

Why this is all important, and how you can stay ahead of the game




## Why this is important

- Re-sets every year
- Maintain competitive position
- Benefits
- Profitability



## What you can do

- Monitor risk scores
- Concurrent review
  - “real time” review of members
- Retrospective review
  - Use historical medical and drug data to identify “suspects”
  - Identify dropped diagnoses (esp. chronic conditions)
  - Provider review



## Methods for diagnosis collection

- Claims
- Chart reviews
- Home visits
- Health risk assessment forms

# Q&A



# Caveats, limitations, and qualifications

This information is prepared for the exclusive use of participants in this webinar hosted by Milliman. This information may not be shared with any third parties without the prior written consent of Milliman. This information is not intended to benefit such third parties, even if Milliman allows distribution to such third parties.

Matt Kridgen, Ali Heinrich, and Jason Choi are Actuaries for Milliman, members of the American Academy of Actuaries, and meet the Qualification Standards of the Academy to render the actuarial

opinion contained herein. To the best of our knowledge and belief, this information is complete and accurate and has been prepared in accordance with generally recognized and accepted actuarial principles and practices.

This information is intended to provide the audience information on plan funding and various revenue streams in Medicare Advantage. This information may not be appropriate and should not be used for any other purposes.

All opinions expressed during the course of this presentation are strictly the opinions of the presenters. Milliman is an independent firm and provides unbiased research and analysis on behalf of many clients. Milliman does not take any specific position on matters of public policy.